ReviewHNO2025
[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 1: Hypersensitivity reactions of type IVa-c as a correlate to T1, T2, and T3 endotypes].
Review in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic rhinosinusitis (CRS) affects up to 11% of the population in Europe and the USA, making it one of the most common chronic diseases. The classification of immunological endotypes, particularly the T2 endotype, is gaining increasing importance. This classification is based on the Coombs and Gell hypersensitivity model, which categorizes cell-mediated type IV reactions into T1, T2, and T3 endotypes. In chronic rhinosinusitis with nasal polyps (CRSwNP), genetic and epigenetic alterations in the mucosal immune system play a key role. Identifying specific endotypes helps to better understand the heterogeneity of the disease and develop tailored treatment approaches. This paper aims to systematize the underlying immunological mechanisms and highlight their relevance for diagnosis and therapy.
methodsThe European Academy of Allergy and Clinical Immunology (EAACI) recently published an updated nomenclature for immunological hypersensitivity reactions. The original Coombs and Gell classification of antibody-mediated reactions (type I-III) has been expanded. Cell-mediated reactions now include: type IVa (T1) → Th1-dominated reactions; type IVb (T2) → Th2-dominated reactions; type IVc (T3) → Th17-dominated reactions. These new insights into T1, T2, and T3 signaling pathways form the basis of this study. Additional mechanisms such as epithelial barrier defects (type V), chemical reactions (type VI), and metabolism-related immune dysregulations (type VII) are addressed separately.
resultsEndotyping reveals distinct regional differences: The T2 (Th2-high) endotype, predominant in Europe, North and South America, and Australia, is characterized by elevated Th2 cytokines (IL‑4, IL‑5, IL-13) and eosinophilic inflammation. The T1 (Th1-high) endotype shows dominant interferon-gamma activity and non-eosinophilic, mainly neutrophilic inflammation. The T3 (Th17-high) endotype is defined by increased IL-17 presence and can occur in both eosinophilic and non-eosinophilic CRSwNP.
conclusionIn CRSwNP patients, all three hyperreactivity endotypes (T1, T2, T3) can occur individually or in combination. The T2 endotype is the most common in Europe. Targeted endotyping enables differentiated treatment approaches and novel therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.